Healthy Skepticism Library item: 6613

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Mansfield P, Vitry A.
Re: the promotion of Adifax (dexfenfluramine)
1995 Dec;

Abstract:

Servier claims that Adifax (dexfenfluramine) reduces high risk viseral fat by 31%. According to the scientific literature there are significant adverse effects associated with this drug. In addition, the significance of regional fat is unclear and whether use of Adifax achieves long-term weight reduction is unknown.

Keywords:
*analysis/Australia/developed countries/Adifax/dexfenfluramine/Servier/safety & risk information/ appetite stimulants and suppressants/ obesity/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES/PROMOTION IN SPECIFIC THERAPEUTIC AREAS: WEIGHT GAIN AND LOSS